Suzi Kochar, MD
Endocrinology, Diabetes & Metabolism · Goodyear, AZNPI 1528387834
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,738 of the $11,214 with a category attached, or 77.9%. It is spread thinly across 47 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations.
Across 572 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$2K
- Novo Nordisk$2K
- AstraZeneca$842
- Abbott$660
- Cequr Corporation$485
- AbbVie$454
- plus $4K from 41 others
What the payments were for
- Speaking & faculty fees$2,01318%
- Travel & lodging$1241%
- Food & beverage$8,73878%
- Education$3393%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$1,686
- CeQur Simplicity$413
- Eversense$400
- FreeStyle Lite system$250
- FARXIGA$125
- Kerendia$122
- Wegovy$119
How this compares
$11,214 in reported general payments places this provider in the 80th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
See all endocrinology, diabetes & metabolism providers in Arizona →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RecorlevLevoketoconazole | 19 | $452,922 |
| OzempicSemaglutide | 180 | $288,009 |
| MounjaroTirzepatide | 185 | $228,946 |
| JardianceEmpagliflozin | 166 | $170,164 |
| TrulicityDulaglutide | 98 | $131,497 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 83 | $100,274 |
| FarxigaDapagliflozin Propanediol | 60 | $75,491 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $72,624 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $60,040 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 28 | $47,468 |
| Humalog Kwikpen U-200Insulin Lispro | 11 | $44,780 |
| JanuviaSitagliptin Phosphate | 35 | $40,370 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $28,024 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $27,328 |
| Humalog Kwikpen U-100Insulin Lispro | 67 | $24,748 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Xeris Pharmaceuticals, Inc.Recorlev | $336 | $452,92219 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $342 | $382,403340 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $2,123 | $314,768221 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $189 | $197,074196 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $206 | $100,27483 claims |
| AstraZenecaFarxiga | $842 | $75,49160 claims |
| MerckJanuvia | $51 | $40,37035 claims |
| Mannkind CorporationAfrezza | $233 | $18,59112 claims |
| AbbVieSynthroid | $454 | $10,39494 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $87 | $7,013740 claims |
| Cequr CorporationCequr Simplicity | $485 | $4,62011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.
Other endocrinology, diabetes & metabolism in Goodyear
- Muhammad SethiTucson$670K
- Kevin YuenPhoenix$404K
- Amir HarariScottsdale$361K
- Joan BaileyPhoenix$316K
- Kristina BlohmScottsdale$220K
- Karen HerbstTucson$200K
- Laura KnechtCave Creek$142K
- Andrea FerencziScottsdale$132K
- Nora BarsonyTucson$121K
- Vidhyalakshmi KannanMesa$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.